Skip to main content

Table 2 Responses to neoadjuvant therapy

From: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

  FAS (n = 35) Surgery set (n = 32)
RECIST
 Complete response, n (%) 3 (8.6%) 3 (9.4%)
 Partial response, n (%) 22 (62.9%) 22 (68.7%)
 Stable disease, n (%) 7 (20.0%) 7 (21.9%)
 Progressive disease, n (%) 0 0
 Objective response rate, % (95% CI) 71.4% (53.7% to 85.4%) 78.1% (60.0% to 90.7%)
 Disease control rate, % (95% CI) 91.4% (76.9% to 98.2%) 100% (89.1% to 100.0%) *
Tumor regression grade, n (%)
 Grade 0 0 0
 Grade Ia 12 (34.3%) 12 (37.5%)
 Grade Ib 4 (11.4%) 4 (12.5%)
 Grade II 13 (37.1%) 13 (40.6%)
 Grade III 2 (5.7%) 2 (6.2%)
Pathological response, n (% [95% CI]) 11 (31.4% [16.8% to 49.3%]) 11 (34.4% [18.6% to 53.2%])
  1. *One-sided
  2. FAS full analysis set, RECIST Response Evaluation Criteria in Solid Tumors, CI confidence interval